KDM4A

Lysine-specific demethylase 4A · O75164 · KDM4A on Sugi Atlas →

57,548 patent compounds predicted against KDM4A, 33,307 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Hydrochloric Acid (SCHEMBL247487)	0.69	12/20
SCHEMBL219327	0.68	12/20
SCHEMBL247791	0.64	12/20
Hydrochloric Acid (SCHEMBL246147)	0.59	12/20
SCHEMBL280327	0.52	12/20
SCHEMBL329005	0.50	12/20
SCHEMBL247779	0.49	12/20
Butyric Acid (SCHEMBL145707)	0.42	12/20
SCHEMBL131476	0.40	11/20
SCHEMBL103141	0.33	10/20
Deferoxamine (SCHEMBL119983)	0.84	9/20
Deferoxamine (SCHEMBL34571)	1.00	8/20
Deferoxamine (SCHEMBL119982)	0.92	8/20
Bromide (SCHEMBL313907)	0.97	6/20
Bromide (SCHEMBL313908)	0.97	6/20
SCHEMBL70700	0.78	6/20
Bromide (SCHEMBL284742)	0.67	6/20
Bromide (SCHEMBL285125)	0.67	6/20
SCHEMBL83586	0.53	6/20
SCHEMBL48443	0.40	6/20

Clinical trials — most relevant to KDM4A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes	PHASE1/PHASE2	COMPLETED
ARID1A and/or KDM6A Mutation and CXCL13 Expression	PHASE2	ACTIVE_NOT_RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Chidamide Combined With Toripalimab in Sarcoma	PHASE2	COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE1	UNKNOWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Safety and Pharmacokinetic Profile of CKD-581	PHASE1	COMPLETED
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders	nan	COMPLETED
Lysine-specific Demethylase 1 and Salt-sensitivity in Humans	nan	ACTIVE_NOT_RECRUITING
The Danish TURNER Cryopreservation Study	nan	RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19	nan	COMPLETED
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer	nan	UNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer	nan	UNKNOWN
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome	nan	COMPLETED
Mechanisms of Immune Deficiency	nan	UNKNOWN
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia	nan	UNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
MIF Involvement in AML	nan	ACTIVE_NOT_RECRUITING
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy	nan	COMPLETED
The Crosstalk Between the Epigenome and Mitochondria in SCI	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a KDM4A binder may also engage these)

Protein	Name	Similarity
Q8BW72	—	1.000	Q8BW72 →
Q5RD88	—	1.000	Q5RD88 →
Q8BMD7	—	0.997	Q8BMD7 →
BRPF3	Bromodomain and PHD finger-containing protein 3	0.997	landscape →
KDM4C	Lysine-specific demethylase 4C	0.997	landscape →
KDM4B	Lysine-specific demethylase 4B	0.996	landscape →
Q08BS4	—	0.996	Q08BS4 →
Q8VCD7	—	0.996	Q8VCD7 →
Q7TMI3	—	0.996	Q7TMI3 →
KDM2B	Lysine-specific demethylase 2B	0.994	landscape →
A0A1W2PPD8	—	0.994	A0A1W2PPD8 →
Q12756	—	0.993	Q12756 →
Q4R381	—	0.993	Q4R381 →
Q9D1P2	—	0.993	Q9D1P2 →
Q2KHP8	—	0.992	Q2KHP8 →
P79922	—	0.992	P79922 →
Q60575	—	0.992	Q60575 →
Q13415	—	0.992	Q13415 →
Q6IVY4	—	0.992	Q6IVY4 →
Q9NRR4	—	0.992	Q9NRR4 →
Q80TM9	—	0.992	Q80TM9 →
Q60L58	—	0.992	Q60L58 →
Q9GYI0	—	0.992	Q9GYI0 →
Q61T02	—	0.992	Q61T02 →
Q95LP3	—	0.992	Q95LP3 →
Q8WML3	—	0.992	Q8WML3 →
Q9H329	—	0.992	Q9H329 →
KAT6A	Histone acetyltransferase KAT6A	0.992	landscape →
Q8VDU5	—	0.991	Q8VDU5 →
B2RRD7	—	0.991	B2RRD7 →